Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Oncopeptides in connection with a directed share issue (3)
Mandate

Vinge advises Oncopeptides in connection with a directed share issue

May 11, 2020 Capital Markets and Public M&A

The board of directors of Oncopeptides has resolved on a directed new issue of shares, whereby Oncopeptides will raise proceeds of approximately SEK 1,414 million, before issue costs.

The share issue is directed to a number of selected international and Swedish reputable investors and life sciences specialist investors, on the basis of an accelerated bookbuilding process conducted by Carnegie Investment Bank AB (publ), Cowen, DNB Markets, a part of DNB Bank ASA, Jefferies International Limited and Kempen & CO N.V.

 

Oncopeptides is a clinical development pharmaceutical company focused on conducting anti‑cancer research to develop treatments for the benefit of patients. The company’s shares are admitted to trading on Nasdaq Stockholm.

 

Vinge’s team has consisted of Dain Hård Nevonen, Sofie Bjärtun, Linnéa Sellström and Hampus Olsson.

 

Related

Vinge advises Sobro on its investment in Västkustens Konstruktionsbyrå

 Västkustens Konstruktionsbyrå has decided to broaden its ownership structure by bringing in Sobro as a new co-partner and majority shareholder. The founders will remain with the company as the CEO and CTO respectively, and as significant shareholders. Västkustens Konstruktionsbyrå is an engineering consultancy company based in Gothenburg with cutting-edge expertise in project management, civil engineering and design.
April 23, 2026

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of SEK 350 million before transaction costs.
April 22, 2026

Vinge has advised Alder on the establishment of Alder Strategic Opportunities Fund I and on a fund credit facility agreement in connection with the fundraising

 Vinge has advised Alder on the establishment of the continuation fund Alder Strategic Opportunities Fund I AB. In connection with the establishment, the fund acquires the portfolio companies SI and SMG from Alder II. Vinge also advised Alder on the entering into of a fund credit facility agreement with SEB.
April 20, 2026